Christina M. Croney

Christina M. Croney

Auto-generated profile, based on publicly available information

Christina M. Croney

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
DKDongsub Kim
Dongsub Kim
HLHaejeong Lee
Haejeong Lee
JCJoon-Sik Choi
Joon-Sik Choi
CCChristina M. Croney
Christina M. Croney
KPKi-Sup Park
Ki-Sup Park
YKYae-Jean Kim
Yae-Jean Kim
Kim D, et al. J Korean Med Sci. 2022 Jun;37(24):e196. https://doi.org/10.3346/jkms.2022.37.e196

1 January 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
JWJulie A. Wolfson
Julie A. Wolfson
SBSmita Bhatia
Smita Bhatia
RBRavi Bhatia
Ravi Bhatia
MSMark W. Smith
Mark W. Smith
CDChen Dai
Chen Dai
KKKelly M. Kenzik
Kelly M. Kenzik
Individuals diagnosed with cancer age between 15 and 39 years (adolescents and young adults [AYAs]) have not seen improvement in survival compared with children or older adults; clinical trial accrual correlates with survival. Unique unmet needs among AYAs related to psychosocial support and fertility preservation (FP) are associated with health-related quality of life. We enhanced existing structures and leveraged faculty/staff across pediatric/adult oncology to create novel teams focused on AYA (age 15-39 years) care at a single center, with minimal dedicated staff and no change to revenue streams. We aimed to influence domains shown to drive survival and health-related quality of life: clinical trial enrollment, physician/staff collaboration, psychosocial support, and FP. We captured metrics 3 months after patients presented to the institution and compared them before/after Program implementation using descriptive statistics. Among 139 AYAs (age 15-39 years) from the pre-Program era (January 2016-February 2019: adult, n = 79; pediatric, n = 60), and 279 from the post-Program era (February 2019-March 2022: adult, n = 215; pediatric, n = 64), there was no change in clinical trial enrollment(P ≥ .3), whereas there was an increase in the proportion of AYAs referred for supportive care and psychology (pediatric: P ≤ .02; adult: P ≤ .001); whose oncologists discussed FP (pediatric: 15% v 52%, P < .0001; adult: 37% v 50%, P = .0004); and undergoing FP consults (pediatric: 8% v39%, P < .0001; adult 23% v 38%, P = .02). This team-based framework has effected change in most targeted domains. To affect all domains and design optimal interventions, it is crucial to understand patient-level and facility-level barriers/facilitators to FP and clinical trial enrollment.